Jul 5, 2024, 02:30
Ipilimumab and Nivolumab for patients with unresected advanced Hepatocellular Carcinoma – ESMO
ESMO shared on LinkedIn:
“Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced Hepatocellular Carcinoma.
Read the opinion piece by Angela Lamarca on ESMO Daily Reporter.”
Source: ESMO/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 22, 2024, 00:56
Oct 22, 2024, 00:49
Oct 22, 2024, 00:40
Oct 22, 2024, 00:34
Oct 22, 2024, 00:24
Oct 21, 2024, 19:26
Oct 21, 2024, 19:21